Cover Image
市場調查報告書

僵直性脊椎炎:開發中產品分析

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229775
出版日期 內容資訊 英文 163 Pages
訂單完成後即時交付
價格
Back to Top
僵直性脊椎炎:開發中產品分析 Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2016
出版日期: 2016年11月16日 內容資訊: 英文 163 Pages
簡介

僵直性脊椎炎是關節炎的一種,影響脊椎。主要的症狀有頸部到腰部的疼痛或僵硬(僵直化)等。此外也會侵害整體脊樑骨,造成脊椎僵直化。這樣的變化會緩慢,或是急速發生,最終造成脊樑骨完全彎曲。

本報告提供全球各國治療僵直性脊椎炎所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

僵直性脊椎炎概要

治療藥的開發

  • 僵直性脊椎炎開發中產品:概要
  • 僵直性脊椎炎開發中產品:比較分析

各企業開發中的僵直性脊椎炎治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 不明確的階段有的產品

僵直性脊椎炎治療藥:開發中的產品一覽(各企業)

僵直性脊椎炎治療藥的開發企業

  • Amgen Inc.
  • Avesthagen Limited
  • BIOCAD
  • Biocon Limited
  • Bionovis SA
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • Celltrion, Inc.
  • Coherus BioSciences, Inc.
  • Epirus Biopharmaceuticals, Inc.
  • Genor BioPharma Co., Ltd.
  • Hetero Drugs Limited
  • Inbiopro Solutions Pvt. Ltd.
  • Innovent Biologics, Inc.
  • Johnson & Johnson
  • Lupin Limited
  • Mabion SA
  • Mabtech Limited
  • Momenta Pharmaceuticals, Inc.
  • Mycenax Biotech Inc.
  • Novartis AG
  • Oncobiologics, Inc.
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Protalix BioTherapeutics, Inc.
  • Sandoz International GmbH
  • Shanghai Pharmaceutical Co., Ltd.
  • Therapeutic Proteins International, LLC
  • Vitae Pharmaceuticals, Inc.
  • Xbrane Bioscience AB

僵直性脊椎炎:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • Adalimumab的生技仿製藥
  • apremilast
  • BI-655066
  • certolizumab pegol biosimilar
  • COVA-322
  • DNX-114
  • DNX-514
  • 依那西普(Etanercept)的生技仿製藥
  • golimumab
  • golimumab的生技仿製藥
  • IBI-303
  • IBPM-004AM
  • IBPM-005IX
  • Infliximab的生技仿製藥
  • INV-17
  • secukinumab k
  • 薩利德邁
  • tofacitinib
  • VTP-43742

僵直性脊椎炎治療藥:開發中產品的最新趨勢

僵直性脊椎炎治療藥:開發暫停的產品

僵直性脊椎炎治療藥:開發中止的產品

僵直性脊椎炎相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8639IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ankylosing Spondylitis - Pipeline Review, H2 2016, provides an overview of the Ankylosing Spondylitis (Musculoskeletal Disorders) pipeline landscape.

Ankylosing spondylitis is a type of arthritis that affects the spine. Ankylosing spondylitis symptoms include pain and stiffness from the neck down to the lower back. The spine's bones (vertebrae) may grow or fuse together, resulting in a rigid spine. These changes may be mild or severe, and may lead to a stooped-over posture.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ankylosing Spondylitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ankylosing Spondylitis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ankylosing Spondylitis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 7, 2, 7, 2, 13, 6 and 2 respectively.Ankylosing Spondylitis.

Ankylosing Spondylitis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Ankylosing Spondylitis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ankylosing Spondylitis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ankylosing Spondylitis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ankylosing Spondylitis (Musculoskeletal Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ankylosing Spondylitis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ankylosing Spondylitis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Ankylosing Spondylitis (Bekhterev's Disease) Overview
  • Therapeutics Development
    • Pipeline Products for Ankylosing Spondylitis (Bekhterev's Disease) - Overview
  • Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics under Development by Companies
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Ankylosing Spondylitis (Bekhterev's Disease) - Products under Development by Companies
  • Ankylosing Spondylitis (Bekhterev's Disease) - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Alteogen Inc.
    • Amgen Inc.
    • BIOCAD
    • Biocon Limited
    • Bionovis SA
    • Brickell Biotech, Inc.
    • Celgene Corporation
    • Coherus BioSciences, Inc.
    • Genor BioPharma Co Ltd
    • Innovent Biologics, Inc.
    • Johnson & Johnson
    • Momenta Pharmaceuticals, Inc.
    • Mycenax Biotech Inc.
    • NeuClone Pty Ltd
    • Novartis AG
    • Oncobiologics, Inc.
    • Panacea Biotec Limited
    • Protalix BioTherapeutics, Inc.
    • Reliance Life Sciences Pvt. Ltd.
    • Sandoz International GmbH
    • Shanghai Pharmaceutical Co., Ltd.
    • Therapeutic Proteins International, LLC
    • Vitae Pharmaceuticals, Inc.
    • Xbrane Biopharma AB
  • Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • adalimumab biosimilar - Drug Profile
    • apremilast - Drug Profile
    • BBI-6000 - Drug Profile
    • certolizumab pegol biosimilar - Drug Profile
    • DNX-114 - Drug Profile
    • DNX-514 - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • etanercept biosimilar - Drug Profile
    • golimumab - Drug Profile
    • golimumab biosimilar - Drug Profile
    • golimumab biosimilar - Drug Profile
    • infliximab biosimilar - Drug Profile
    • infliximab biosimilar - Drug Profile
    • infliximab biosimilar - Drug Profile
    • infliximab biosimilar - Drug Profile
    • infliximab biosimilar - Drug Profile
    • infliximab biosimilar - Drug Profile
    • infliximab biosimilar - Drug Profile
    • infliximab biosimilar - Drug Profile
    • INV-17 - Drug Profile
    • risankizumab - Drug Profile
    • secukinumab - Drug Profile
    • thalidomide - Drug Profile
    • upadacitinib tartrate - Drug Profile
    • VTP-43742 - Drug Profile
  • Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects
  • Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products
  • Ankylosing Spondylitis (Bekhterev's Disease) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by AbbVie Inc, H2 2016
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Alteogen Inc., H2 2016
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Amgen Inc., H2 2016
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by BIOCAD, H2 2016
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biocon Limited, H2 2016
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Bionovis SA, H2 2016
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Brickell Biotech, Inc., H2 2016
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Celgene Corporation, H2 2016
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Coherus BioSciences, Inc., H2 2016
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Genor BioPharma Co Ltd, H2 2016
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Innovent Biologics, Inc., H2 2016
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Johnson & Johnson, H2 2016
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Mycenax Biotech Inc., H2 2016
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by NeuClone Pty Ltd, H2 2016
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Novartis AG, H2 2016
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Oncobiologics, Inc., H2 2016
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Panacea Biotec Limited, H2 2016
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Protalix BioTherapeutics, Inc., H2 2016
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2016
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Sandoz International GmbH, H2 2016
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Shanghai Pharmaceutical Co., Ltd., H2 2016
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Therapeutic Proteins International, LLC, H2 2016
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Vitae Pharmaceuticals, Inc., H2 2016
  • Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Xbrane Biopharma AB, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects, H2 2016
  • Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects (Contd..1), H2 2016
  • Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top